Cargando…

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

CONTEXT: Hepatitis C virus (HCV) infection is a major cause of liver-morbidity and mortality among patients with thalassemia. Peginterferon plus ribavirin is currently the recommended therapy for hepatitis C infection in patients do not have thalassemia, but using ribavirin in patients with thalasse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aminizadeh, Ehsan, Alavian, Seyed Moayyed, Akbari Sari, Ali, Ebrahimi Daryani, Nasser, Behnava, Bita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876663/ https://www.ncbi.nlm.nih.gov/pubmed/27226796 http://dx.doi.org/10.5812/hepatmon.28537

Ejemplares similares

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran
por: Mehrazmay, Alireza, et al.
Publicado: (2013)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2010)

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
por: Dolatimehr, Fardin, et al.
Publicado: (2017)

Low Dose Ribavirin for Treatment of Hepatitis C Virus Infected Thalassemia Major Patients; New Indications for Combination Therapy
por: Tabatabaei, Seyed Vahid, et al.
Publicado: (2012)

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
por: Behnava, Bita, et al.
Publicado: (2016)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis
por: Alavian, Seyed-Moayed, et al.
Publicado: (2012)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?
por: Abbasinazari, Mohammad, et al.
Publicado: (2013)

A Woman with Recent Jaundice and Pruritus
por: Behnava, Bita, et al.
Publicado: (2010)

Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, November 2011, Tehran, Iran
por: Alavian, Seyed Moayed, et al.
Publicado: (2012)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C
por: Masaki, Naohiko, et al.
Publicado: (2014)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
por: Ide, Kazuki, et al.
Publicado: (2016)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013
por: Ebrahimi Daryani, Nasser, et al.
Publicado: (2013)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2017)

IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report
por: Mahboobi, Nastaran, et al.
Publicado: (2011)

Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin
por: Jafroodi, Maryam, et al.
Publicado: (2011)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2014)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report
por: EL-Atrebi, Kamal, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_fpv5irsbh9k6n52l3uajscep6q